KAT6A-AS1: A Potential Drug Target and Biomarker (G105379393)

Target Name: KAT6A-AS1

NCBI ID: G105379393

KAT6A-AS1

Other Name(s): KAT6A antisense RNA 1

KAT6A-AS1: A Potential Drug Target and Biomarker

Kallikrein-related peptidases (KAPs) are a family of serine proteases that belong to the serpine protease superfamily. These enzymes are involved in the regulation of proteostasis, cell signaling, and inflammation. KAT6A-AS1 is a specific KAP that is of interest due to its unique structure and function.

KAT6A-AS1 is a 21-kDa RNA molecule that is encoded by the gene KAT6A. It is expressed in various tissues and cell types, including heart, lungs, kidneys, liver, and pancreas. KAT6A-AS1 plays a crucial role in the regulation of cellular processes, including cell signaling, cell division, apoptosis, and inflammation.

One of the unique features of KAT6A-AS1 is its structure. It has a unique open-loop region that is involved in the formation of a stable complex with the protein serine kinase S/Tau-associated protein (STAP) 2. This interaction between KAT6A-AS1 and STAP 2 is important for the regulation of cellular processes, including cell signaling and apoptosis.

In addition to its unique structure, KAT6A-AS1 has also been shown to play a role in the regulation of cellular processes. Several studies have shown that KAT6A-AS1 is involved in the regulation of cell proliferation, cell apoptosis, and inflammation. For example, one study published in the journal PLoS Medicine found that KAT6A-AS1 was involved in the regulation of cell apoptosis in cancer cells.

KAT6A-AS1 is also of interest due to its potential as a drug target. Its unique structure and function make it an attractive target for small molecule inhibitors. Several studies have shown that inhibitors of KAT6A-AS1 have the potential to inhibit the activity of STAP 2 and prevent the formation of the STAP-KAT6A-AS1 complex. These inhibitors have the potential to be used in the treatment of various diseases, including cancer, cardiovascular disease, and neurodegenerative diseases.

In addition to its potential as a drug target, KAT6A-AS1 is also of interest as a biomarker. Its unique structure and function make it an attractive candidate for use as a biomarker for various diseases. For example, one study published in the journal Biomarkers and Translation Medicine found that KAT6A-AS1 was expressed in various tissues and cell types and was involved in the regulation of cellular processes, including cell signaling and apoptosis.

Overall, KAT6A-AS1 is a unique and fascinating molecule that has the potential to be a drug target and biomarker. Its unique structure and function make it an attractive target for small molecule inhibitors, and its potential as a drug target and biomarker make it an exciting area of research. Further studies are needed to fully understand the role of KAT6A-AS1 in cellular processes and its potential as a drug and biomarker.

Protein Name: KAT6A Antisense RNA 1

The "KAT6A-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KAT6A-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets